Dr. Moorthy’s research focuses on liquid chromatography-tandem mass spectrometry assays for translational research. He is an expert in developing and validating analytical methods and their implementation for pediatric and adult clinical sample analysis.
The research interests of Dr. Downes focus on antimicrobial clinical pharmacology and pharmacoepidemiology in children with a goal to identify novel approaches to optimize efficacy, minimize toxicity, and limit antimicrobial resistance from antibiotics.
Dr. Balis's research focuses on the clinical pharmacology of anticancer drugs, new drug development, and clinical trial design and endpoints. He studies the pharmacokinetics and pharmacodynamics of anticancer drugs and has applied pharmacological principles to clinical trial design and clinical drug development. He is developing new biomarkers to serve as surrogate endpoints of drug toxicity or efficacy in clinical trials.
The Moorthy Lab focuses on liquid chromatography-tandem mass spectrometry assays for translational research. The lab evaluates and uses new tools and microsampling technologies to facilitate preclinical, translational, and clinical research.
The Investigational Drug Service (IDS) component of Children’s Hospital of Philadelphia's Department of Pharmacy Services complements the institution's clinical research mission in advancing new therapeutic modalities.
Revolutionizing our understanding of the genetic causes and mechanisms of hyperinsulinism, developing diagnostic tools for a precision-medicine approach to treatment, and discovering new treatment options.
The Cancer Pharmacology Laboratory supports clinical trials of new mechanistically targeted and immune-based anticancer drugs by conducting pre-clinical and clinical pharmacology studies of the agents. The lab also studies conventional anticancer drugs to develop more rational and effective dosing methods, and the lab team is developing circulating biomarkers of organ function, drug toxicity, and tumor burden as clinical trial endpoints.